Recruiting studies: Raf Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629 DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178 A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06610682 A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Phase 1 · 23 location(s) · Nested Therapeutics, Inc · NCT06326411 PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.